The Brand Name RELMISART Has Generic Salt :: Telmisartan 

RELMISART  Is From Company LA RENON Priced :: Rs. 60

RELMISART have Telmisartan is comes under Sub class Anti Hypertensives of  Main Class Cardiovascular System

Main Medicine Class:: Cardiovascular System  Sub Medicine Class :: Anti Hypertensives 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
Telmisartan  TAB  Rs. 60  10
Brand Name Company / Manufacturers Strength Unit Price / 10

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From LA RENON :: RELMISART  Telmisartan  Cardiovascular System Anti Hypertensives

Indications for Drugs ::

Hypertension, Diabetic nephropathy

Drug Dose ::

Oral Hypertension Adult: Initially, 40 mg once daily, may be adjusted to 20-80 mg once daily if needed. Hepatic impairment: Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated. Oral Cardiovascular risk reduction Adult: 80 mg once daily. Hepatic impairment: Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated.

Contraindication ::

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

Drug Precautions ::

Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.

Drug Side Effects ::

URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes. Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.

Pregnancy category ::
Pregnancy category


Drug Mode of Action ::  

Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.

Drug Interactions ::

May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 ml>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Related Posts:
You May Also Like::